+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 926037-48-1
926037-48-1,MFCD27956910
Catalog No.:AA00H1GL

926037-48-1 | Radotinib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98+%
in stock  
$8.00   $6.00
- +
5mg
98+%
in stock  
$19.00   $14.00
- +
10mg
98+%
in stock  
$28.00   $20.00
- +
25mg
98+%
in stock  
$45.00   $32.00
- +
100mg
98+%
in stock  
$105.00   $74.00
- +
250mg
98+%
in stock  
$168.00   $117.00
- +
1g
98+%
in stock  
$453.00   $317.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00H1GL
Chemical Name:
Radotinib
CAS Number:
926037-48-1
Molecular Formula:
C27H21F3N8O
Molecular Weight:
530.5038
MDL Number:
MFCD27956910
SMILES:
Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2nccnc2)C)cc(c1)C(F)(F)F
Properties
Computed Properties
 
Complexity:
818  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
39  
Hydrogen Bond Acceptor Count:
10  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
6  
XLogP3:
3.9  

Downstream Synthesis Route
641571-11-1    926038-04-2   
Radotinib 

[1]Patent:WO2010/18895,2010,A1.Locationinpatent:Page/Pagecolumn7

641571-11-1    1207665-71-1   
Radotinib 

[1]Patent:WO2010/18895,2010,A1.Locationinpatent:Page/Pagecolumn7

641571-11-1    1207665-72-2   
Radotinib 

[1]Patent:WO2010/18895,2010,A1.Locationinpatent:Page/Pagecolumn8

4-methyl-N-3-(4-methyl-1H-imidazolyl)-5-trifluoromethylphenyl-3-guanidinobenzamidenitrate 
  111781-53-4   
Radotinib 

[1]CurrentPatentAssignee:ANHUIHERYIPHARMACEUTICAL-CN111039932,2020,ALocationinpatent:Paragraph0023;0028-0030;0035-0038;0043-0045

Literature

Title: Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.

Journal: Leukemia 20150901

Title: Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Journal: Haematologica 20140701

Title: Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Journal: Nature reviews. Cancer 20120724

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 926037-48-1
926037-85-6

926037-85-6

 641571-10-0

641571-10-0

 923288-90-8

923288-90-8

 1246817-85-5

1246817-85-5

 1268356-17-7

1268356-17-7

 1215678-43-5

1215678-43-5
Building Blocks
More >
Tags:926037-48-1 Molecular Formula|926037-48-1 MDL|926037-48-1 SMILES|926037-48-1 Radotinib